The IBS Status is a unique profile that will assess the overall health of the gastrointestinal (GI) tract. It is a non-invasive evaluation that uses biotechnology to evaluate digestion, inflammation, and gut flora. The benefit of this test is that you can quickly identify causes of chronic GI complaints while delivering timely targeted treatment, including identifying whether or not a more invasive procedure like a colonoscopy is required.
What is tested?
Inflammation Calprotectin – Faecal calprotectin is a unique marker to differentiate irritable bowel disease (IBD) from irritable bowel syndrome (IBS). It is a neutrophilic protein measured in the stool offering an objective, quantifiable indication of GI-specific inflammation. Calprotectin has been demonstrated to correlate with disease activity via histology and endoscopic visualisation.
Digestion Pancreatic Elastase PE – Digestion Pancreatic Elastase PE is a non-invasive marker of pancreatic function. It correlates well with the secretin pancreozymin procedure for diagnosis of moderate and severe pancreatic insufficiency (PI) and can effectively rule-out chronic PI in cases of chronic diarrhoea, which is a common presentation in those ultimately diagnosed with IBS.
Infection – Infectious organisms should be considered within cases of abdominal pain and altered bowel habits. Although food borne illness may produce acute symptoms other infectious organisms may also cause chronic illness. Giardia, Cryptosporidium and Entamoeba histolytica are widely recognised as prevalent, pathogenic parasites, however, Blastocystis hominis has been proposed to have a causative role within symptoms of some IBS patients.
Clostridium difficile – Formerly regarded as predominantly a nosocomial infection, clostridium difficile has recently been identified in community acquired settings and infects up to 3% of the national populous.
Allergy Eosinophil Protein X (EPX) – Allergic responses can play a causative role within chronic diarrhoea. EPX is a cationic protein, which is released from eosinophils during inflammation, and can be measured within the stool. Although non-specific, evaluation of EPX offers physicians an indication of eosinophilic activity associated with food allergy or parasitic infection.
RESULTS: 7-10 Business Days